Doctors already knew that semaglutide, the active ingredient in Ozempic and Wegovy, could make people with obesity-related heart failure feel better. What they did not know was exactly what the treatment was changing inside the heart.
A study published November 8, 2026, in Nature Medicine offers one of the most detailed answers yet. Researchers at Mayo Clinic used cardiac magnetic resonance imaging, or MRI, to examine heart structure and function before and after 52 weeks of treatment.
The results suggest that semaglutide improves how the heart receives blood, reduces some unfavorable structural changes and helps explain why pressure inside the heart falls during exercise.
The evidence comes from a randomized, placebo-controlled clinical trial in humans. But the imaging analysis was small: 49 participants, including just 16 receiving placebo.
And although Ozempic contains the same active ingredient, the trial used semaglutide 2.4 mg weekly, the dose associated with Wegovy. It was not a trial specifically administering branded Ozempic.
The distinction matters because the study is about semaglutide’s biological effects, not a head-to-head comparison of commercial products.
The condition is heart failure with preserved ejection fraction, or HFpEF. The heart can still pump out a relatively normal proportion of the blood inside its main pumping chamber, but filling becomes impaired and pressures can rise sharply, especially during physical activity.
For patients, that can mean breathlessness, fatigue and difficulty exercising despite a heart that appears to pump normally on standard measurements.
The new research asks a more specific question: when semaglutide improves this condition, what changes can doctors actually see?
What the Mayo Clinic CAMEO-SEMA Trial Tested
The new paper is a prespecified cardiac MRI substudy of CAMEO-SEMA, a clinical trial registered as NCT05371496.
The parent study, also published November 8 in Nature Medicine, randomly assigned 81 patients with obesity-related HFpEF to receive semaglutide 2.4 mg once weekly or placebo for 52 weeks.
Its primary objective was not to measure weight loss or examine heart scans. It was to determine whether semaglutide reduced pulmonary artery wedge pressure during low-intensity exercise.
Pulmonary artery wedge pressure, or PAWP, is measured invasively using a catheter. It provides an estimate of pressure on the left side of the heart, including the pressure that can build up when the heart struggles to fill.
At baseline, average wedge pressure was 17.5 mmHg at rest and 31.7 mmHg during exercise.
After 52 weeks, exercise wedge pressure had fallen by an average of 9.8 mmHg in the semaglutide group, compared with an increase of 0.9 mmHg in the placebo group.
The estimated between-group difference was a reduction of 10.6 mmHg, with a reported p-value below 0.0001.
Resting wedge pressure also fell significantly compared with placebo.
In a further analysis, 53.7% of semaglutide-treated participants met the trial’s definition of hemodynamic remission, compared with 7.4% receiving placebo.
That definition required normal wedge pressures at rest and during exercise at 52 weeks. It should not be confused with a permanent clinical cure of heart failure.
The MRI substudy then investigated the structural and functional changes that might explain these pressure improvements.
Of the parent trial participants, 49 completed cardiac MRI at baseline and again at 52 weeks. Thirty-three had received semaglutide, 16 had received placebo, and 28 were women.
Each imaging assessment was performed within one day of the invasive exercise testing.
That pairing is the study’s distinguishing strength. Researchers could compare changes visible on MRI with changes in pressure measured directly inside the cardiovascular system.
The MRI study was led by first author Fahime Ghanbari, with Mayo Clinic cardiologist Barry Borlaug as senior author. Heart failure researcher Milton Packer was also among the co-authors.
The study did more than photograph the heart. It connected changes in cardiac function with pressure measurements taken during exercise.
What Changed in the Heart After 52 Weeks of Semaglutide
The prespecified primary MRI endpoint was left atrial reservoir strain.
The left atrium is the chamber that receives oxygen-rich blood returning from the lungs. During ventricular contraction, the atrium acts as a reservoir, stretching to accommodate incoming blood.
Reservoir strain measures that stretching function. Impaired atrial strain can reflect the abnormal pressures and chamber interactions associated with HFpEF.
Compared with placebo, semaglutide improved left atrial reservoir strain by 5.7 percentage points.
The reported 95% confidence interval ranged from an improvement of 0.3 to 9.7 percentage points, with a p-value of 0.037.
That is statistically significant under the conventional 0.05 threshold. But the confidence interval is wide, and its lower bound sits close to zero, reflecting uncertainty about the precise size of the effect.
The second important measure concerned how quickly the left ventricle fills with blood early in each heartbeat.
Researchers measured the early filling rate indexed to end-diastolic volume, abbreviated eFR/EDV.
Semaglutide improved this measure by 0.64 per second compared with placebo, with a 95% confidence interval of 0.42 to 1.00 and a p-value below 0.0001.
In practical terms, the treated patients showed improved early filling dynamics in the heart’s main pumping chamber.
That finding is relevant because impaired ventricular filling is one of the defining physiological problems in HFpEF.
The researchers then examined whether the imaging changes tracked with the invasive pressure measurements.
Improvements in left atrial reservoir strain were associated with reductions in exercise wedge pressure, with a correlation coefficient of -0.46.
The relationship was stronger for improved ventricular filling dynamics, where the reported correlation was -0.65.
Those negative correlations mean that participants showing greater improvement in the MRI measurements tended to show larger reductions in pressure during exercise.
The association supports a physiological connection, although it cannot establish that the imaging changes themselves caused the pressure reductions.
Beyond these measures, the authors reported reductions in left ventricular mass, movement toward more physiological ventricular geometry and improvements in right ventricular function and the mechanics of both ventricles.
Taken together, the findings suggest that semaglutide’s effects in obesity-related HFpEF may extend beyond how much weight a patient loses or how well the patient reports feeling.
They do not, however, prove that the drug directly changes the underlying stiffness of heart muscle tissue.
How the MRI Results Compare With Earlier Heart Failure Research
Semaglutide’s clinical benefits in obesity-related HFpEF were already established before the new MRI paper.
The larger STEP-HFpEF research program showed improvements in heart failure-related symptoms, physical limitations, exercise function and body weight among patients receiving semaglutide 2.4 mg weekly.
But the mechanisms responsible for these improvements remained uncertain.
An echocardiography substudy published in the Journal of the American College of Cardiology in 2024 examined 491 participants drawn from the STEP-HFpEF and STEP-HFpEF DM trials.
That analysis found semaglutide slowed adverse enlargement of the left atrium and right ventricle compared with placebo.
However, it did not find a statistically significant treatment effect on left ventricular mass or left atrial reservoir strain.
The newer CAMEO-SEMA MRI substudy reports improvements in both.
Those differences deserve attention, but they are not necessarily contradictory.
The studies involved different patient populations, used different cardiac imaging techniques and evaluated different endpoints.
Echocardiography uses ultrasound, while cardiac MRI can provide detailed measurements of chamber volumes, mass and myocardial motion.
Different measurement techniques can produce different estimates of subtle structural and functional changes.
At the same time, 49 patients cannot definitively resolve findings from an imaging study nearly ten times larger.
The two datasets are best treated as complementary evidence pointing toward a possible effect on cardiac remodeling, with further confirmation needed.
The broader story also includes tirzepatide, Lilly’s dual GIP and GLP-1 receptor agonist.
In a secondary analysis of the SUMMIT trial published in Nature Medicine, investigators found that tirzepatide reduced systolic blood pressure, estimated circulating blood volume and inflammatory markers in people with obesity-related HFpEF.
That study provided another possible explanation for why incretin-based therapies improve heart failure symptoms: reducing the circulatory burden that the heart must accommodate.
Those mechanisms are not mutually exclusive. Weight loss, changes in blood volume, improved metabolic conditions and alterations in cardiac structure may all contribute to the clinical response.
Grey Pepper has examined related questions in its coverage of semaglutide and kidney tissue research, where investigators similarly looked beyond standard clinical outcomes to investigate what changes inside an organ.
Weight loss may explain part of the benefit. The unresolved question is how much of the improvement comes from changes in the heart itself.
What the 49-Person MRI Study Cannot Prove
The first limitation is sample size.
Although the parent CAMEO-SEMA trial randomized 81 patients, the MRI substudy included only 49 people with imaging available at baseline and after 52 weeks.
Of those, 33 received semaglutide and just 16 received placebo.
That imbalance means the comparison group was relatively small. A handful of unusual measurements can materially influence the estimated difference between treatments.
It also matters that the MRI analysis included a subset of the parent trial rather than every randomized participant. The published abstract does not provide enough information to determine whether those with complete imaging differed meaningfully from participants who were not included.
The second limitation concerns mechanism.
The findings show improved filling dynamics, chamber function and associated reductions in filling pressure. They do not isolate the relative contributions of weight loss, reduced circulating blood volume or potential direct actions on cardiac tissue.
A heart may fill more favorably because it is exposed to less pressure and volume loading, not necessarily because the material properties of the heart muscle have changed.
That distinction is important when describing the results as evidence of reduced stiffness.
Third, the MRI endpoints are physiological measurements rather than hard clinical outcomes such as hospitalization or death.
The study was not designed to establish that changes in atrial strain or ventricular filling independently prevent future heart failure events.
Fourth, the study followed patients for one year.
It does not show whether the improvements persist over several years or what happens to the heart’s structure and filling dynamics after semaglutide is discontinued.
These questions matter because obesity-related HFpEF is a chronic condition, and long-term treatment decisions depend on sustained benefits, safety and tolerability.
Finally, the findings concern patients with HFpEF and obesity. They should not automatically be generalized to people with reduced-ejection-fraction heart failure, people without obesity or patients without heart failure.
The publicly accessible journal abstract also does not provide the full accounting of trial funding and competing interests. Those disclosures should be assessed in the complete publication when available.
The study is stronger than an uncontrolled observation because treatment was randomized and compared with placebo. Its size and mechanistic limitations nevertheless place boundaries around what can reasonably be concluded.
Why the Findings Matter for the Next Generation of Heart Failure Research
HFpEF has historically been difficult to treat because it is not one disease with a single underlying cause.
Patients can have different combinations of obesity, hypertension, diabetes, impaired kidney function, inflammation and abnormalities in cardiac filling.
That complexity helps explain why treatments effective in other forms of heart failure have not always produced the same benefits in HFpEF.
Obesity-related HFpEF has become an especially important research target because excess adiposity can contribute to elevated circulating blood volume, increased cardiac workload and metabolic disturbances.
Semaglutide and tirzepatide have changed the treatment conversation by demonstrating clinically meaningful benefits in selected patients with this form of heart failure.
But knowing that patients feel better is only one part of understanding why a treatment works.
The new MRI findings offer researchers a more detailed set of physiological measurements to investigate.
Left atrial reservoir strain, early ventricular filling rate, ventricular mass and cardiac geometry could help reveal which aspects of heart function respond to metabolic treatment.
Future studies could assess these changes in larger populations, compare their relationships with weight loss and blood volume, and determine whether they predict longer-term clinical outcomes.
They could also help researchers compare how different incretin-based medicines affect the heart.
That is relevant as pharmaceutical companies develop additional GLP-1 combinations and multi-receptor agonists intended to produce greater metabolic effects.
Grey Pepper has previously examined the difficulty of interpreting real-world cardiovascular comparisons between Ozempic and Mounjaro. Mechanistic randomized studies can help answer different questions, but their findings still require appropriate clinical validation.
The most useful next step would be a larger cardiac imaging study with sufficient statistical power to test changes in heart structure and function, paired with longer follow-up and clinical outcomes.
Researchers also need to establish whether the structural and functional effects are sustained and whether they are primarily consequences of weight loss or reflect additional pharmacological actions.
For now, the results provide a meaningful piece of the mechanistic puzzle.
In a small randomized MRI substudy, a year of semaglutide improved measurements of how the left atrium stretches and how the left ventricle fills. Those changes were associated with lower exercise filling pressures.
The findings strengthen the biological explanation for semaglutide’s effects in obesity-related HFpEF. They do not establish a direct effect on myocardial stiffness or prove that the imaging improvements will translate into fewer hospitalizations or deaths.
The important finding is not simply that patients felt better. In 49 people, researchers could see measurable improvements in heart function. The next question is which of those changes explain the benefit, and whether they hold up in larger trials.
Sources and Further Reading
- Ghanbari F, et al. Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial. Nature Medicine, November 8, 2026.
- Borlaug BA, et al. Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial. Nature Medicine, November 8, 2026.
- ClinicalTrials.gov. CAMEO-SEMA: Evaluation of Cardiac and Metabolic Effects of Semaglutide in Heart Failure. NCT05371496.
- Solomon SD, et al. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure. Journal of the American College of Cardiology, 2024.
- Journal of the American College of Cardiology. Correction to Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure, March 2025.
- Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nature Medicine, November 2024.
